This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics

SAVINGS DEADLINE EXPIRES IN:

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
May 14-17, 2024 | In-Person + Digital
Boston, MA, USAHynes Convention Center

Dr. Jonathan Rittichier, PhD
Chief Scientific Officer & Co-Founder at EnPlusOne BioSciences
Speaker

Profile

Jonathan is co-founder and CSO of EnPlusOne Bio. He did his postdoc in George Church’s Research Group at Harvard Medical School and the Wyss Institute for Biologically Inspired Engineering, where he co-developed the enzymatic RNA synthesis platform that formed the basis of EnPlusOne technology. During his postdoc, he jointly developed methods for tRNA charging and chemically accessing new, nonstandard amino acids. Jonathan earned his BS in Chemistry from Indiana Wesleyan University and a PhD in Organic Chemistry from Indiana University under Professor Michael Vannieuwenhze.

Agenda Sessions

  • A Platform for Controlled Template-Independent Enzymatic Synthesis of RNA Oligonucleotides and Therapeutics

    9:00am